Endothelin and cardiovascular remodelling in end-stage renal disease

被引:86
|
作者
Demuth, K
Blacher, J
Guerin, AP
Benoit, MO
Moatti, N
Safar, ME
London, GM
机构
[1] Hop Manhes, Serv Nephrol Hemodialyse, F-91700 Fleury Merogis, France
[2] Broussais Hop, Dept Biochem, Paris, France
[3] INSERM, U337, Paris, France
关键词
endothelin; ESRD; cardiovascular remodelling;
D O I
10.1093/oxfordjournals.ndt.a027833
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background. Plasma endothelin (ET) is elevated in end-stage renal disease (ESRD), but the origin and consequences of this increase remain unclear. In the present study we analysed the relationships between plasma ET levels and cardiovascular alterations in ESRD. Methods and results. Common carotid artery (CCA) intima-media thickness (IMT) and diameter, atherosclerotic plaque occurrence, and left ventricular (LV) geometry and function were determined by ultrasound imaging in 76 haemodialysis patients and in 57 age-, sex-, and blood pressure-matched controls. Arterial stiffness was evaluated via carotid-femoral pulse wave velocity (CF-PWV), forearm post-ischaemic vasodilation was measured by venous plethysmography, and plasma ET levels were determined using a specific immunoenzymoassay. Compared with controls, ESRD patients had elevated plasma ET levels (1.6 +/- 1.4 vs 4.6 +/- 3.8 pg/ml; P < 0.001), increased LV mass (P < 0.001), increased CCA-IMT (P < 0.001), a higher prevalence of atherosclerotic plaques (P < 0.001) and increased CF-PWV (P < 0.01). Plasma ET levels correlated positively with LV outflow velocity integral(r = 0.57; P < 0.0001), stroke index (P < 0.01), and baseline forearm blood flow (P < 0.001) which were all significantly higher in ESRD patients than in controls (P < 0.01). After adjustment for age, blood pressure, haemoglobin levels, gender and body dimensions, plasma ET levels were significantly correlated to LV mass (r = 0.46; P < 0.001), CCA-IMT and CCA intima -media cross-sectional area (r = 0.41; P < 0.001), and CF-PWV (P < 0.05). Post-ischaemic forearm vasodilation was decreased in ESRD (85 +/- 31 vs 119 +/- 28%; P < 0.001) and there was a negative correlation between post-ichaemic flow recovery and ET levels (r = -0.49; P < 0.001). In ESRD patients, plasma ET levels were positively and independently correlated with the prevalence of CCA atherosclerotic plaque (P < 0.01). Conclusions. These results indicate that the increased plasma ET levels in ESRD patients are associated with left ventricular hypertrophy and arterial intima-media thickening, suggesting that increased ET concentrations in ESRD patients may be of pathophysiological significance in the process of cardiovascular remodelling.
引用
收藏
页码:375 / 383
页数:9
相关论文
共 50 条
  • [41] METABOLIC SYNDROME AND CARDIOVASCULAR DISEASE RISK IN END-STAGE RENAL DISEASE PATIENTS
    Coimbra, S.
    Reis, F.
    Nunes, S.
    Viana, S.
    Rocha, S.
    Valente, M. J.
    Catarino, C.
    Rocha-Pereira, P.
    Bronze-Da-Rocha, E.
    Oliveira, J. G.
    Fernandes, J. C.
    Madureira, J.
    Faria, M. D. S.
    Miranda, V.
    Belo, L.
    Santos-Silva, A.
    ATHEROSCLEROSIS, 2022, 355 : E250 - E251
  • [42] Traditional and emerging cardiovascular risk factors in end-stage renal disease
    Zoccali, C
    Mallamaci, F
    Tripepi, G
    KIDNEY INTERNATIONAL, 2003, 63 : S105 - S110
  • [43] Circulating proteins as predictors of cardiovascular mortality in end-stage renal disease
    Tobias Feldreich
    Christoph Nowak
    Tove Fall
    Axel C. Carlsson
    Juan-Jesus Carrero
    Jonas Ripsweden
    Abdul Rashid Qureshi
    Olof Heimbürger
    Peter Barany
    Peter Stenvinkel
    Nicolas Vuilleumier
    Philip A. Kalra
    Darren Green
    Johan Ärnlöv
    Journal of Nephrology, 2019, 32 : 111 - 119
  • [44] Wasting, but not malnutrition, predicts cardiovascular mortality in end-stage renal disease
    Stenvinkel, P
    Heimbürger, O
    Lindholm, B
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2004, 19 (09) : 2181 - 2183
  • [45] Antioxidant enzymes and cardiovascular risk factors in end-stage renal disease
    Fytili-Kavakiotou, C. A.
    Gounari, E.
    Zisi, F.
    Daskalaki, M.
    Hatzikallinikidou, E.
    Progia, E.
    ATHEROSCLEROSIS SUPPLEMENTS, 2006, 7 (03) : 77 - 77
  • [46] Strategies to decrease cardiovascular mortality in patients with end-stage renal disease
    Dikow, R
    Adamczak, M
    Henriquez, DE
    Ritz, E
    KIDNEY INTERNATIONAL, 2002, 61 : S5 - S10
  • [47] Progression of arterial stiffness and cardiovascular risk in end-stage renal disease
    Blacher, J
    Safar, M
    Guerin, A
    Pannier, B
    Marchais, S
    Asmar, R
    London, G
    JOURNAL OF HYPERTENSION, 2000, 18 : S190 - S190
  • [48] CARDIOVASCULAR-DISEASE IN PATIENTS WITH END-STAGE RENAL-FAILURE
    GREAVES, SC
    SHARPE, DN
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1992, 22 (02): : 153 - 159
  • [49] Insulin resistance as a predictor of cardiovascular morbidity and end-stage renal disease
    Fragoso, Andre
    Mendes, Filipa
    Silva, Ana Paula
    Neves, Pedro Leao
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2015, 29 (08) : 1098 - 1104
  • [50] Fosinopril could reduce cardiovascular events in end-stage renal disease
    Nature Clinical Practice Nephrology, 2007, 3 (2): : 64 - 64